Anti-Alzheimer Activity of Hydroalcoholic Extract of Butea monosperma leaves by Joshi, Ankur & Malviya, Neelesh
Joshi et al                                                                                                                  Journal of Drug Delivery & Therapeutics. 2019; 9(2-A):62-67 
ISSN: 2250-1177                                                                                     [62]                                                                                    CODEN (USA): JDDTAO 
Available online on 25.04.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                          Research Article 
Anti-Alzheimer Activity of Hydroalcoholic Extract of Butea monosperma 
leaves 
Joshi Ankur*1, Malviya Neelesh2 
1 Research Scholar, Mandsaur University, Mandsaur, Modern Institute of Pharmaceutical Sciences, Indore, M.P., India  
2 Smriti College of Pharmaceutical Education, Indore, M.P., India 
 
ABSTRACT 
Objective: The key objective of the study is to evaluate Anti-Alzheimer activity of hydroalcholic extracts of Butea monosperma leaves (BMLE) 
by streptozotocin induced Alzhemier. Butea monosperma (Lam.) is medium size tree belonging to family Leguminoceae. It is reported to have 
numerous uses in the indigenous system of medicine in India.  
Material and Methods: AD was induced by streptozotocin i.e. STZ (3 mg/kg, ICV) day 1st and 3rd day after surgery. Surgery was done on 
anesthetized rats by the help of stereotaxic apparatus. STZ induced AD rats were treated with ethanolic extracts of Butea monosperma (100 
and 200 mg/kg, p.o.) for 14 days. Effect of BMLE in AD rats were assessed by estimating inflexion ratio in EPM and the alteration in the 
behavior (Y maze apparatus), biochemical parameter in the brain tissue acetylcholinesterase (AchE) .  
Result: The preliminary phytochemical investigation of BMLE showned the presence of carbohydrates, alkaloids, flavonoids, phenols, ta nnins, 
saponins, fixed oil, vitamin C, proteins and amino acids.Extracts at dose levels of 100 mg/kg and 200 mg/ kg showed a significant elevation in 
inflexion ratio in elevated plus maze and elevation in percentage alternation in Y-maze model. A significant decline in brain AChE level was 
noted in animals treated with extracts in both models.  
Conclusion: These results suggest that, the Anti-Alzheimer effect of BMLE might be due to enhancement of cholinergic neurotransmission 
through inhibition of AChE activity.  
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INTRODUCTION 
Alzheimer's disease is one of the most common 
neurodegenerative disease that has been characterized by 
the progressive impairment of cognitive function, changes in 
behavior 1. Cholinergic hypo-function plays a basic role in 
cognitive dysfunction and memory loss. 2. Pathology of AD 
constitutes neuronal loss in the basal forebrain particularly 
within the septo-hippocampal cholinergic systems involved 
in the learning and memory processes. Various 
cholinomimetics drugs have been approved for the 
management of AD.  
These drugs show therapeutic effects by acting on 
acetylcholine deficits and, consequently, increase 
acetylcholine levels in the brain 3. Dementia is a term used 
for memory loss and other intellectual abilities that are 
severe enough to disrupt daily activities later in life 4. The 
most common types of dementia include Alzheimer's disease 
(AD), cerebrovascular dementia, dementia with Lewy bodies, 
frontotemporal dementia and Parkinson's disease 5. AD is the 
most common type of dementia and is responsible for 50-
60% of all cases 6 
AD is a progressive neurodegenerative brain disease. AD is 
characterized by memory loss and behavioral changes 7. 
Memory loss is usually the main symptom of the AD. The 
therapeutic approach in the treatment of AD is the use of 
AChE inhibitors (acetylcholinesterase inhibitors). AChEI 
blocks the activity of acetylcholinesterase that normally 
breaks down acetylcholine (ACh). 
The inhibition of this acetylcholinesterase prevents the 
decomposition of acetylcholine, which is known to be 
deficient in AD. 8 
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Tacrine (AchEI) is the first drug approved for treatment of 
AD 9. Though, tacrine has many disadvantages, such as low 
bioavailability, narrow therapeutic window and 
hepatotoxicity in the treatment of AD 10. 
Other acetylcholine esterase inhibitor such as donepezil, 
rivastigmine and galantamine have limited therapeutic 
success as they only improve memory in mild dementia and 
cannot stop the process of neurodegeneration 11. Butea 
monosperma (Lam.) belonging to the family Leguminoceae.It 
is reported to have numerous uses in the indigenous system 
of medicine in India.  
Various medicinal properties are reported are 
hepatoprotective activity, astringent, aphrodisiac, and tonic 
properties. In the ancient time various parts are to treat 
disease like night blindness, elephantiasis, anorexia, 
constipation, inflammation, gonorrhoea, burning urine etc. 
Streptozotocin (STZ), a glucosamine-nitrosourea compound 
derived from soil bacteria and originally developed as an 
antitumor agent, was found in 1963 to induce diabetes in 
experimental animals. Since then, the systemic application of 
STZ has become the most studied experimental model of 
insulin-dependent diabetes (type 1). The compound is 
selectively toxic to pancreatic beta-producing insulin cells, 
which is explained as a result of its cellular uptake by the low 
affinity glucose transporter protein 2 (GLUT2) located in its 
cell membranes. The cytotoxicity of STZ is mainly due to the 
alkylation of DNA that causes cell necrosis. In addition to 
pancreatic beta cells, the applied STZ also systematically 
damages other organs that express GLUT2, such as the 
kidney and the liver, while the brain is not directly affected 
because the blood-brain barrier lacks this transporter 
protein (Fig. 1). However, single or double injection of 
intracerebroventricular STZ (icv) chronically reduces 
glucose uptake in the brain and produces many other effects 
that resemble the molecular, pathological and behavioral 
characteristics of Alzheimer's disease (AD)  
 
 
Figure 1: Streptozotocin Meachanism of Action for Induction of Alzhemier’s disease 
 
MATERIAL AND METHODS  
Preparation of the extract.  
The leaves of butea monosperma were collected in the local 
area of the city of Indore and authenticated. The leaves were 
washed, dried in the air under shade and powdered.  50 g of 
powdered drug was subjected to soxhletion with 
hydroalcoholic solution in the ratio of 70:30. 
Extraction was done at temperature of 50 ° C until the clear 
solvent was observed in the siphon tube. The extract was 
concentrated in a water bath at 40 ° C. The concentrated 
extract was then dried at 40 ° C in a hot air oven. The dried 
extract has been packed in an airtight container.  
Phytochemical screening  
The extract obtained was subjected to preliminary 
phytochemicals screening. The extracts were examined for 
alkaloids, flavonoids, phenols, tannins, saponins, fixed oil, 
vitamin C, proteins and amino acids, glycosides, flavonoids, 
terpenoids, tannins 16-17.  
Acute toxicity studies  
In this study, male Wistar rats weighing 250-300 g were 
used. They had free access to food and water ad libitum. 
Acute toxicity studies have been conducted in accordance 
with OECD (Organization for Economic Cooperation and 
Development) guidelines n. 425 (Up and Down procedure). 
It was found that the test samples were safe up to 2000 mg / 
kg. The protocol were approved by the Institutional Animal 
Ethics Committee under the CPSCEA. (IAEC / MIPS / 
01/2017/04)  
Group I: Normal control  
Group II: Streptozotocin (3 mg / kg) (Negative control)  
Group III: Donepezil (5 mg / kg) + Streptozotocin (3 mg / kg) 
) (Positive control)  
Group IV: BMLE (100 mg / kg + streptozotocin (3 mg / kg)  
Group V: BMLE (200 mg / kg) + streptozotocin (3 mg / kg) 
Induction of Alzheimer:  
MaleWistar rats (250-300 g) were anesthetized by 
intraperitoneal injection of a combination of ketamine and 
xylazine (100 and 5 mg / kg, respectively) and then all rats 
were operated with a stereotaxic apparatus. . 
For the surgery, the stereotactic apparatus (Pxinos and 
Watson) were used, the scalp was washed with iodine 
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solution, it was recorded in the midline and drilled through 
the post bregma skull of 0.8 mm, 1.4 mm laterally from the 
sagittal line and 3.4 mm below the dura mater. The STZ 
groups received a bilateral ICV injection of streptozotocin (3 
mg / kg, body weight) which was dissolved in the citrate 
buffer (pH 4.4). 
The concentration of STZ was prepared to provide 5 μl / site 
of injection of the solution. The rats in the control group 
received an ICV injection of the same volume of citrate buffer 
compared to the treated STZ and the injection was repeated 
on the third day 18. Elevated Plus Maze: The EPM functioned 
as a model of exteroceptive behavior (in which the stimulus 
existed outside the body) to evaluate learning and memory 
in rats. 
 
 
Figure 2: Induction of Alzheimer’s Disease 
 
Elevated Plus Maze 
The elevated plus maze consisted of two open arms (50 cm x 
10 cm x 40 cm) and two closed arms (50 cm x 10 cm x 40 
cm), with an open roof, arranged so that the two arms open 
one in front of the another The maze was raised to a height of 
50 cm from the ground to measure the anxiety index in rats. 
19-21 It is a simple test of recognition of two tests to measure 
the memory of spatial recognition, it does not require the 
learning of a rule and, therefore, it is useful for the study of 
memory in rodents. 
 Y Maze  
The Y Maze consists of three arms with an angle of 120 ° 
between each of the two arms. The dimensions of the arm 
are 8 cm x 30 cm x 15 cm (width x length x height). The three 
identical arms were designated randomly: the initial arm, in 
which the rats began to explore (A), the new arm (B, with 
food stimuli) and the other arm (C). 22 Mice tend to 
systematically explore the maze, inserting each arm in turn. 
On the first day, all rats were allowed to explore Y Maze for a 
period of ten minutes each. From the 2nd to the 5th day, the 
rats received four consecutive training sessions per day in 
the maze that lasted 8 minutes. In each trial, the rats were 
placed in the entrance chamber (A) and the range of arm 
entry in all three arms was visually recorded, including 
possible return in the same arm. The modification is defined 
as the number of successive entries in the three arms in sets 
of overlapping triplets. 
The alteration rate is calculated as the total number of 
entries in the arm minus two and multiplied by 100. The 
amnestic pretreatment 30 minutes before the tests induces a 
marked decrease in the performance of the spontaneous 
alteration with a concomitant increase in the total number of 
the arm. It is expected that the administration of agents that 
have memory improvement effects will reverse the changes. 
During the evaluation of the learning, the animals were 
exposed to water and food ad libitum for only 1 hour after 
the exposure of the maze of the day was completed to ensure 
motivation towards the reward area (B). 23 
Estimation of ACh levels in the brain by quantifying AChE 
inhibition: 
Brain cholinesterase activity was measured using the Ellman 
method [24]. An aliquot of 0.4 ml of the prepared 
homogenate was added to a cuvette containing 2.6 ml of 
sodium phosphate buffer (pH 7.2, 0.1 M). 
To this, 100µl of Ellman's reagent (DTNB) was added and 
taken into a photocell. The absorbance was set to zero at 412 
nm when the fluctuations stopped. of the substrate (Acetyl 
thiocholine iodide) 20µl was added. A change in the 
absorbance per minute was noted Calculations AChE activity 
is calculated using the following formula  
Calculations 
AChE activity is calculated using the following formula 
 
Where, 
ΔA = Change in absorbance per minute 
C0 = Original concentration of the tissue (mg/ml) 
R = Rate in moles substrate hydrolyzed per minute 
per gram of tissue 
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RESULT AND DISCUSSION  
Phytochemical Screening 
The preliminary phytochemical analysis of ethanol extract of 
Butea monosperma leaves showed the presence of 
carbohydrates, alkaloids, flavonoids, phenols, tannins, 
saponins, fixed oil, vitamin C, proteins and amino acids. Acute 
oral toxicity study of Butea monosperma was carried out as 
per OECD guideline 425. From the limit test results, it was 
ob- served that the Butea monosperma leaves were safe up to 
a dose level of 2000 mg/kg. There was no mortality and the 
experimental animals did not show any toxic effect throughout 
the observation period of 14 days. 
Elevated Plus maze 
The effect of the vehicle, streptozotocin control, Butea 
monosperma (100 and 200 mg/kg) and Donepezil (5mg/kg) 
were evaluated at the end of days 7 and 14. The 
streptozotocin (1 mg/kg) control group showed a significant 
increase in TL values on the acquisition as well as on the 
retention days as compared with vehicle control rats, 
indicating impairment in learning and memory. In the AT on 
day 7 and day 14, the Butea monosperma at dose levels 100 
and  200 mg/kg demonstrated decrease in the TL as 
compared to the streptozotocin control group. The results 
obtained were found to be statistically significant . Donepezil 
(5mg/kg) exhibited marked decrease in TL in comparison 
with the streptozotocin control group. However, Butea 
monosperma at the dose levels 100 and 200 mg/kg showed a 
decrease in the TL, which is comparable to that shown by 
Donepezil [Table 1]. 
 
Table 1: Effect of the extract of Butea monosperma on transfer latency (elevated plus maze paradigm) in 
streptozotocin-induced amnesia in rats 
Groups  Treatment  TL on acquisition day (sec) 
7 day 14 day 
Group I Normal Control  94.17±13.92 35.83±5.89 
Group II Streptozotocin (3mg/kg) (Negative Control) 140.67±17.2ns 117.8±11.03ns 
Group III Donepezil (5mg/kg) + Streptozotocin (3mg/kg) (Positive Control) 48.17±5.21*** 7.33±2.13*** 
Group IV Butea monosperma(100mg/kg+ Streptozotocin (3mg/kg) 52.5±4.75** 17.33±4.73** 
Group V Butea monosperma(200mg/kg)+ Streptozotocin (3mg/kg) 26.5±6.67** 15.33±3.05** 
All values are expressed as mean ± S.E.M, n = 6 in each group. Values are significantly different from group I control; ns - non-significant; P values: * 
< 0.05, ** < 0.01, ***< 0.001 (Student t. test analysis). b Values are significantly different from group II negative control, ns- non significant, P values: * < 
0.05, ** < 0.01,
*** 
< 0.001 (one way ANOVA followed by Dunnett’s test) 
 
Y maze Model 
Y maze model used in the present study proved to be a 
sensitive measure of spatial recognition memory. The effect 
on alteration behavior was studied on two parameters, % 
alteration (Table 2) and No. of arm entries (Table 3). 
Effect on % alteration: Normally rats exhibit an alteration of 
around 60-70% as exhibited by the normal group (Group 1). 
Group 3 achieving a slightly higher alteration than the 
vehicle group (Group 1). The alteration showcased by 
Groups 1, 3 is indicative of the natural tendency of rats to 
exhibit an alteration of around 60-70% in a 5 min session, 
however the alteration achieved on the second trial (Day 14) 
was higher elaborating higher % alteration (ability to 
alternate) on account of acquisition of memory. Group 2 
exhibited a marked decrease in spontaneous alteration (a 
characteristic feature of amnestic agents), elaborating the 
amnestic effects of streptozotocin, however in Groups 4-5; 
there was a significant increase in % alteration thus 
supporting their memory enhancing effects to reverse the 
effects of streptozotocin. The greatest alteration was 
achieved by the standard Donepezil; in presence of amnesia 
(Group 4) followed by the higher dose of Butea monosperma 
extract in presence of amnesia (Group 5). It succeeded in 
closely approximating the alteration response of the 
standard Donepezil. Assuming generalization % alteration on 
Day 14 was found to be greater than that observed on Day 
13, thus elucidating the retention characteristics of the 
purported nootropics  
 
Table 2: Effect of the extract of Butea monosperma on Assessment of learning and memory using Y Maze Apparatus % 
Alteration 
Groups  Treatment  % Alteration 
% Alteration on Day 
13 
% Alteration 
on Day 14 
Group I Normal Control 65.50±0.072 71.25±0.087 
Group II Streptozotocin (3mg/kg) (Negative Control) 42.38± 0.594ns 53.33± 0.259ns 
Group III Donepezil (5mg/kg)+Streptozotocin (3mg/kg) (Positive Control) 69.33±0.594*** 71.49±0.389*** 
Group IV Butea monosperma(100mg/kg+ Streptozotocin (3mg/kg) 65.42±0.277** 69.14±0.260** 
Group V Butea monosperma(200mg/kg)+ Streptozotocin (3mg/kg) 62.56±0.371** 65.43±0.313** 
All values are expressed as mean ± S.E.M, n = 6 in each group. Values are significantly different from group I control; ns - non-significant; P values: * 
< 0.05, ** < 0.01, ***< 0.001 (Student t. test analysis). b Values are significantly different from group II negative control, ns- non significant, P values: * < 
0.05, ** < 0.01,
*** 
< 0.001 (one way ANOVA followed by Dunnett’s test) 
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Table 3: Effect of the extract of Butea monosperma on Assessment of learning and memory using Y Maze Apparatus by 
Number of Arm Enteries 
Groups  Treatments  Number of Arm entries 
Number of Arm 
entries on Day 
13 
Number of 
Arm entries on 
Day 14 
Group I Normal Control  25.0±0.035 20.0±0.069 
Group II Streptozotocin (3mg/kg) (Negative Control) 33.50±0.119ns 30.5±0.257ns 
Group III Donepezil (5mg/kg)+Streptozotocin (3mg/kg) (Positive Control) 13.50±0.218*** 8.0±0.239*** 
Group IV Butea monosperma(100mg/kg+ Streptozotocin (3mg/kg) 24.50±0.757** 18.0±0.719** 
Group V Butea monosperma(200mg/kg)+ Streptozotocin (3mg/kg) 25.5±0.457** 19.5±0.485** 
All values are expressed as mean ± S.E.M, n = 6 in each group. Values are significantly different from group I control; ns - non-significant; P values: * 
< 0.05, ** < 0.01, ***< 0.001 (Student t. test analysis). b Values are significantly different from group II negative control, ns- non significant, P values: * < 
0.05, ** < 0.01,
*** 
< 0.001 (one way ANOVA followed by Dunnett’s test) 
 
Estimation of AChE activity in the brain: 
In the standard group, the animals treated with Donepezil 
(5mg/kg) produced a significant reduction of AChE enzyme 
activity. In the treatment group, the animals treated with 
Butea monosperma  at 100 and 200 mg/kg produced a 
significant reduction of AChE enzyme activity and as 
compared to positive control. Percentage inhibition of AChE 
activity of treatment group has shown a significant increase 
when compared to positive control. [Table 4] 
 
Table 4: Effect of the extract of Butea monosperma on AChE Inhibition Activity 
Groups  Treatment  AChE concentrated (μMol 
/minute/g of tissue) 
Inhibition of AChE 
activity (%) 
Group I Normal Control  6.742±0.18  
Group II Streptozotocin (3mg/kg) (Negative Control) 10.39±0.35ns 35.11ns 
Group III Donepezil (5mg/kg) + Streptozotocin (3mg/kg) (Positive 
Control) 
3.968±0.19*** 61.8*** 
Group IV Butea monosperma(100mg/kg+ Streptozotocin (3mg/kg) 4.907±0.31** 50.12** 
Group V Butea monosperma(200mg/kg)+ Streptozotocin (3mg/kg) 4.967±0.31** 52.19** 
All values are expressed as mean ± S.E.M, n = 6 in each group. Values are significantly different from group I control; ns - non-significant; P values: * 
< 0.05, ** < 0.01, ***< 0.001 (Student t. test analysis). b Values are significantly different from group II negative control, ns- non significant, P values: * < 
0.05, ** < 0.01,
*** 
< 0.001 (one way ANOVA followed by Dunnett’s test) 
 
CONCLUSION  
The present study investigated the Anti-Alzheimer activity of 
hydroalcholic extract of Butea monnosperma leaves in rats 
models. Progressive neurodegeneration in the brain, leading 
to the depletion of acetylcholine (ACh) stores is the primary 
cause of memory loss in the ageing population. Drugs or 
plant swith acetylcholinesterase (AChE) activity can thus 
increase levels of ACh that are known to be depleted in 
neurodegenerative disorders such as Alzheimer’s disease 
(AD) by inhibiting AChE, an enzyme that degrades 
Acetylcholine [25]. In humans, memory is generally accessed 
through spoken or written languages, whereas, in laboratory 
animals, cognitive functions must be accessed through 
behavioral models [26]. Two such models are the transfer 
latency by elevated plus maze and alternation performance 
(SAP) in the Y-maze and object recognition performance. 
Moreover, the streptozotocin used in this study to induce 
amnesia has a high selectivity for the muscarinic receptors, 
especially the M1 receptor subtypes found in the 
hippocampus [27].Cholinergic transmission generally ends 
by the acetylcholine hydrolysis through the enzyme AChE 
which is responsible for degradation of acetylcholine to 
acetate and choline at the level of the synaptic cleft [28]. 
Thus, estimating the acetylcholine esterase activity can 
provide valuable information on cholinergic function. Our 
results in- dicated a decrease in AChE activity in the brain of 
animals pre-treated with Butea monosperma leaf extract 
against streptozotocin induced memory impairment in both 
elevated plus model and Y-maze model. The effect might be 
due the activity of Butea monosperma leaves that produced 
enhancement in cholinergic transmission by potential AChE 
inhibitory activity. 
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